Reported Saturday, Lilly's Taltz And Zepbound Combination Achieves 31.7% ACR50 And 10% Weight Reduction Versus 0.8% For Taltz Alone In TOGETHER-PsA Trial

In the TOGETHER-PsA trial, the combination of Lilly's Taltz and Zepbound achieved a 31.7% ACR50 response and a 10% weight reduction, significantly outperforming Taltz alone, which recorded only a 0.8% response. These results indicate comprehensive improvements in disease activity and patient-reported outcomes. The findings were also published in the journal Arthritis & Rheumatology.